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ABSTRACT – Rationale: Metabolic acidosis induced by topiramate is a well documented but infrequent adverse
event. The objective was to demonstrate the lowering of carbon dioxide serum levels, which is usually
asymptomatic but may facilitate the occurrence of metabolic acidosis in patients using topiramate. Methods: We
evaluated, prospectively, the carbon dioxide serum levels of 18 patients seen at the epilepsy clinic of our university
hospital, before and 3 months after introducing topiramate. Results: Five patients were female and 13 were male,
age ranging from 2 to 16 years old (mean=9.3). Carbon dioxide mean serum levels were 25 and 21.2 mmol/L
(normal = 22 to 30), before and 3 months after introducing topiramate, respectively. Dose ranged from 2.08 to
11.76 mg/kg/day (mean=6.7mg/kg/day). Adverse events were anorexia, nausea and somnolence. Conclusion:
We conclude that the lowering of carbon dioxide serum levels induced by topiramate is mostly asymptomatic,
but may facilitate the occurrence of metabolic acidosis. Since patients in use of topiramate have refractory
epilepsy, they may need epilepsy surgery, and must be carefully monitored for the risk of metabolic acidosis
during surgery.
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Predisposição a acidose metabólica induzida por topiramato
RESUMO – Introdução: Acidose metabólica induzida por topiramato é evento adverso pouco frequente, mas
bem documentado. Nosso objetivo foi demonstrar a diminuição dos níveis de dióxido de carbono, muitas vezes
assintomática, mas que pode predispor ao aparecimento de acidose metabólica. Material e Método: Avaliamos
prospectivamente os níveis de dióxido de carbono de 18 pacientes acompanhados no ambulatório de epilepsia
infantil da UNICAMP, antes e 3 meses após o início do uso de topiramato. Resultados: Foram avaliados 18
pacientes com idade entre 2 e 16 anos (média = 9,3 anos). Cinco pacientes eram do sexo feminino e 13, do sexo
masculino. Os níveis médios de dióxido de carbono antes e após o uso de topiramato foram 25 e 21,2 mmol/L
(normal = 22 a 30), respectivamente. A dose de topiramato utilizada foi 2,08 a 11,76 mg/kg/dia (média = 6,7 mg/
kg/dia). Os eventos adversos mais frequentes foram anorexia, nausea e sonolência. Conclusão: Concluímos que
a diminuição dos níveis de dióxido de carbono induzida por topiramato é na maioria das vezes assintomática
entretanto, pode predispor à ocorrência de acidose metabólica. Como o topiramato é utilizado frequentemente no
tratamento de epilepsia de difícil controle, os pacientes em uso desta medicação quando submetidos à cirurgia de
epilepsia devem ser monitorizados, principalmente durante o intraoperatório, quanto à possibilidade de
apresentarem acidose metabólica.
PALAVRAS-CHAVE: topiramato, acidose metabólica, nefrolitíase.
Topiramate (TPM) is a new antiepileptic drug (AED) used mainly as adjunctive therapy in
partial and secondary generalized epilepsy. Important side effects include dizziness, ataxia, headache,
paresthesia, tremor, somnolence, cognitive dysfunction, confusion, agitation, depression, amnesia,
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emotional lability, diarrhoea, diplopia and weight loss 1. Despite being a safe drug, it may seldom be
associated with serious adverse events such as kidney stones and metabolic acidosis 2.
The objective of this study was to analyze the carbon dioxide (CO
2
) serum levels of 18 patients,
before and during the use of TPM, since this drug may predispose the lowering of CO
2
 serum levels,
which is usually asymptomatic but may facilitate the occurrence of metabolic acidosis.
METHOD
We evaluated, prospectively, the CO
2
 serum levels of patients seen at the epilepsy clinic of our University
Hospital. All patients received TPM as adjunctive therapy for the treatment of severe epileptic encephalopaties
and uncontrolled seizures.
Patients had to be receiving of at least one AED, had no history of kidney stones and could not be using
of any carbonic anhydrase inhibitor either. Blood samples were drawn 15 days before and 3 months after TPM
was introduced. Patients were seen monthly, and adverse events were assessed by physical examination and
parent and/or children interview.
Statistical analysis was done using the Student “t” test for paired mean samples, with a significance level
of 0.05.
Table 1. Characteristics of the patients in use of topiramate.





pre-TPM after-TPM event TPM/kg
SMC 13 F VA+CLB 27 20 Anorexia, 7.69
somnolence
ACS 16 F CBZ+CLB 25 22 - 3.75
WFR 9 M CBZ 24 21 - 6.48
DAC 2 M VA+CLB 23 18  Intestinal 10.00
constipation
GFC 10 F CZP 23 19 - 7.05
LGP 7 M VGB 25 24 - 7.60
GBP 5 M LTG 26 21 - 10.00
TBS 14 M OXC+LTG+CLB 27 23 Somnolence, 4.54
irritability
HRC 4 F FNT+CLB 24 22 - 5.95
RD 14 M OXC 27 25 Somnolence 2.34
AB 7 M CBZ+CLB 26 21 - 11.76
LHG 7 M CBZ+CZP 26 21 Anorexia, 4.09
somnolence
LFA 6 M OXC+NTZ 25 19 - 6.57
GSM 9 M VA+CLB 29 25 Anorexia 11.32
AVL 12 M VGB+CLB 25 19 Somnolence 10.16
diarrhoea
TBS 15 F OXC+VA 23 21 Somnolence 3.60
LVS 8 M LTG+NTZ 24 20 Somnolence 2.08
CAS 10 M FNT+CZP 21 21 Anorexia 5.68
TPM, topiramate; CO2 , carbon dioxide; AED, antiepileptic drug; VA, sodium valproate; CLB, clobazam, CBZ,




Eighteen patients were evaluated, 13 male and 5 were female. Ages ranged from 2 to 16
years-old (mean=9.3 years) and they were all using one or more AED when TPM was introduced
(Table 1).
Carbon dioxide serum levels varied from 21 to 29 mmol/L (mean = 25) and 18 to 25mmol/L
(mean = 21.2), 15 days before and 3 months after starting TPM, respectively, which was statistically
significant (p=6.7 X10-8). The TPM dose varied from 2.08 mg/Kg to 11.6 mg/Kg (mean = 6.7).
Ten patients presented adverse events characterized by anorexia, somnolence, diarrhoea,
irritability and intestinal constipation (Table 1).
DISCUSSION
Topiramate has three properties thought to be antiepileptic: state-dependent blocking of sodium
channels, potentiation of GABA (γ-aminobutyrate), and antagonistic effect on the kainate/AMPA
(α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) subtype of receptor. It also inhibits
isoenzimes of carbonic anhydrase (CA-II and CA-IV) 2.
Despite being a safe drug, and most of the patients do not present any sign of metabolic
acidosis (hyperventilation, confusion, etc.), this is a well documented adverse event induced by
TPM 2-5. Metabolic acidosis is probably due to the carbonic anhydrase inhibitory effect of TPM,
which increases the bicarbonate lost in the urine, and consequently, decreases CO
2 
serum levels 2.
Takeoka et al. 4 reported a 10% lowering in the bicarbonate serum levels in 20 out of 29
children receiving TPM, showing a clear predisposition to metabolic acidosis. After TPM withdrawal,
bicarbonate levels returned to baseline.
Despite our data showed that most of the patients had a decrease in CO
2 
serum levels, they
presented only mild adverse events, and only one had to stop taking TPM due to anorexia. It is hard
to know if there is any relationship between CO
2 
levels and mild adverse events. Although none of
our patients presented metabolic acidosis, the decrease in CO
2 
serum levels may facilitate the
occurrence of severe metabolic acidosis in situations where TPM is associated to the ketogenic diet,
renal disease, dialysis, diarrhea or surgery. The combination of TPM and ketogenic diet or
acetazolamide is contraindicated, not only because the increased risk of metabolic acidosis, but it
may increase the occurrence of nephrolitiasis as well.
The occurrence of kidney stones induced by oral administration of carbonic anhydrase
inhibitors in rats has been demonstrated by Molon-Noblot et al. 6 . The carbonic anhydrase inhibitory
effect of TPM decreases the citrate excretion, with no effect on urinary calcium excretion. The
hypocitraturia caused by TPM is probably the major risk factor for nephrolitiasis 7.
It is believed that nephrolitiasis is an idiosyncratic event, and it is not related to the TPM
dose. In a study of 1200 patients, nephrolitiasis was seen in 18 patients (1.5%) treated with TPM.
They were all male, and ages ranged from 21 to 54 years old. None needed open surgery and ¾ had
spontaneous recovery 8. The incidence of 1.5% of nephrolitiasis associated with TPM is similar to
those presented by other carbonic anhydrase drugs, such as acetazolamide 9,10.
One of the authors (CAMG) followed two patients with clear history of nephrolitiasis after
TPM treatment. One of them, a 17 year-old boy using 400 mg/day of TPM for 4 months and the
other a 32 year-old female using 200 mg/day of TPM for 8 months. She had temporal lobe epilepsy
with hippocampal atrophy shown by MRI, and she was seizure free after TPM therapy, but when the
drug was tapered down seizures relapsed. It was decided to restart TPM and she is seizure free
again, with no new episode of nephrolitiasis in a follow up period of 1 year. Guerreiro et al. 11
reported a 2.5 year-old boy presenting “sand in the urine” after TPM therapy, which probably
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represented the early stages of nephrolitiasis. Symptoms disappeared after the withdrawal of the
drug.
Patients receiving TPM may develop acute confusional state without changing TPM dosages.
This condition may be difficult to diagnose, unless it is clinically suspected. The withdrawal of
TPM (or even only a decrease in its dosage) causes total recovery 3. Severe metabolic acidosis was
reported by Wilner et al. 2 during epilepsy surgery. Carbon dioxide serum levels were 28/29 mM and
24 mM before and after introducing TPM, respectively (both within normal limits). The authors
believe that the metabolic acidosis was caused by an increase in the bicarbonate excretion by TPM,
which became clinically significant during surgery. During the week prior to the surgery, the patient
had presented diarrhea, which may have contributed to the clinical picture, by increasing the loss of
alkali.
Since TPM is currently used mainly in patients with severe forms of refractory epilepsies,
some might need epilepsy surgery. The decrease in CO
2 
serum levels, usually precedes the changes
of serum pH, therefore, the monitoring of CO
2 
or bicarbonate is more precise in detecting subtle
changes of acid-basic equilibrium. It is important to follow the bicarbonate and/or CO
2 
serum levels
throughout visits and specially during surgery, for the risk of metabolic acidosis.
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